Fosamprenavir

Fosamprenavir (FPV), sold under the brand names Lexiva and Telzir, is a medication used to treat HIV/AIDS. It is a prodrug of the protease inhibitor and antiretroviral drugamprenavir. It is marketed by ViiV Healthcare as the calcium salt.

Fosamprenavir was approved for medical use in the United States in October 2003, and in the European Union in July 2004. The human body metabolizes fosamprenavir in order to form amprenavir, which is the active ingredient.

A head-to-head study with lopinavir showed the two drugs to have comparable potency, but patients on fosamprenavir tended to have a higher serum cholesterol.

In August 2026, the FDA withdrew approval of the branded fosamprenavir product (Lexiva) at the request of ViiV Healthcare after the company notified the agency that the drug was no longer marketed. Generic fosamprenavir tablets remain available in the U.S.